Balance and management of CRS and infection following CD19-targeted CAR T-cell therapy in primary refractory high-grade B-cell lymphoma: a case report
BackgroundCD19-targeted chimeric antigen receptor T (CAR T) cell therapy has revolutionized the treatment of refractory/relapsed B-cell malignancies. However, this therapy introduces significant safety concerns, including cytokine release syndrome (CRS) and infections, both of which can lead to life...
Saved in:
| Main Authors: | Nannan Lu, Yajing Zhang, Chunmeng Wang, Qingming Yang, Guanghua Rong, Yang Liu, Weidong Han |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Hematology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/frhem.2025.1616504/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Art of Bioimmunogenomics (BIGs) 5.0 in CAR-T Cell Therapy for Lymphoma Management
by: Dito Anurogo, et al.
Published: (2024-07-01) -
Use of locally produced anti-CD19 CAR-T cells in the treatment of relapsed/refractory B-cell lymphomas in adults
by: N. E. Konoplya, et al.
Published: (2023-09-01) -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA
by: Ugo Testa, et al.
Published: (2023-10-01) -
CAR‐T Cell Therapy for PTLD: Analysis of CAR‐T Product, Engraftment, and Outcomes in Patients Receiving Parallel Immunosuppression
by: Aikaterini Panopoulou, et al.
Published: (2025-02-01) -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS
by: Ugo Testa, et al.
Published: (2024-01-01)